EUSA Pharma and BeiGene Announce Acceptance of a Biologics License Application for QARZIBA®▼ (Dinutuximab Beta) in China
9.11.2020 15:04:00 EET | Business Wire | Press release
EUSA Pharma (UK) Limited and BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160) today announced that the Biologics License Application (BLA) for QARZIBA®▼ (dinutuximab beta) was accepted by the China National Medical Products Administration (NMPA) and granted priority review. Dinutuximab beta is a targeted immunotherapy approved by the European Medicines Agency (EMA) for the treatment of high-risk neuroblastoma in patients aged 12 months and above who have previously received induction chemotherapy and achieved at least a partial response, followed by myeloablative therapy and stem cell transplantation, as well as patients with history of relapsed or refractory neuroblastoma with or without residual disease. High-risk neuroblastoma is an aggressive neoplasm and the most common childhood solid tumour that originates outside of the brain. Dinutuximab beta is listed in the first batch of New Drugs in Urgent Clinical Need Marketed Overseas by the NMPA.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20201109005558/en/
“Dinutuximab beta represents an important biologic, which is already available to patients with high-risk neuroblastoma in Europe,” commented Xiaobin Wu, Ph.D., General Manager of China and President of BeiGene. “For paediatric patients fighting this disease in China, we are hopeful that dinutuximab beta will soon be available as a new treatment option. Our collaboration with EUSA and the progress thus far demonstrate our joint commitment to bringing high-quality therapies to the people who need them.”
Lee Morley, Chief Executive Officer of EUSA Pharma, said, “This milestone brings us and BeiGene closer to delivering on our promise of bringing innovative cancer and rare disease therapies to patients around the world. We look forward to working with BeiGene and the NMPA to potentially make dinutuximab beta available in China.”
About QARZIBA®▼ (dinutuximab beta)
QARZIBA®▼ is a monoclonal antibody that is specifically directed against the carbohydrate moiety of disialoganglioside 2 (GD2), which is overexpressed on neuroblastoma cells. Dinutuximab beta was approved by the European Commission in 2017 and is indicated for the treatment of high-risk neuroblastoma in patients aged 12 months and above, who have previously received induction chemotherapy and achieved at least a partial response, followed by myeloablative therapy and stem cell transplantation, as well as patients with history of relapsed or refractory neuroblastoma, with or without residual disease. Prior to the treatment of relapsed neuroblastoma, any actively progressing disease should be stabilised by other suitable measures. In patients with a history of relapsed/refractory disease and in patients who have not achieved a complete response after first line therapy, dinutuximab beta should be combined with interleukin-2 (IL-2).
About EUSA Pharma
Founded in March 2015, EUSA Pharma is a world-class biopharmaceutical company focused on oncology and rare disease. The company has extensive commercial operations in the United States and Europe, alongside a direct presence in select other markets across the globe. EUSA Pharma is led by an experienced management team with a strong record of building successful pharmaceutical companies and is supported by significant funding raised from leading life science investor EW Healthcare Partners. For more information please visit www.eusapharma.com.
About BeiGene
BeiGene is a global, commercial-stage biotechnology company focused on discovering, developing, manufacturing, and commercializing innovative medicines to improve treatment outcomes and access for patients worldwide. Our 4,700+ employees in China, the United States, Australia, Europe, and elsewhere are committed to expediting the development of a diverse pipeline of novel therapeutics. We currently market two internally discovered oncology products: BTK inhibitor BRUKINSA® (zanubrutinib) in the United States and China, and anti-PD-1 antibody tislelizumab in China. We also market or plan to market in China additional oncology products licensed from Amgen Inc., Celgene Logistics Sàrl, a Bristol Myers Squibb (BMS) company, and EUSA Pharma. To learn more about BeiGene, please visit www.beigene.com and follow us on Twitter at @BeiGeneUSA.
BeiGene Forward Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and other federal securities laws, including statements regarding the potential approval, launch and opportunity of QARZIBA® in China, future development and potential commercialization activities of the products under the agreement with EUSA, and other information that is not historical information. Actual results may differ materially from those indicated in the forward-looking statements as a result of various important factors, including BeiGene's ability to demonstrate the efficacy and safety of its drug candidates; the clinical results for its drug candidates, which may not support further development or marketing approval; actions of regulatory agencies, which may affect the initiation, timing and progress of clinical trials and marketing approval; BeiGene's ability to achieve commercial success for its marketed products and drug candidates, if approved; BeiGene's ability to obtain and maintain protection of intellectual property for its technology and drugs; BeiGene's reliance on third parties to conduct drug development, manufacturing and other services; BeiGene’s limited operating history and BeiGene's ability to obtain additional funding for operations and to complete the development and commercialization of its drug candidates, as well as those risks more fully discussed in the section entitled “Risk Factors” in BeiGene’s most recent quarterly report on Form 10-Q, as well as discussions of potential risks, uncertainties, and other important factors in BeiGene's subsequent filings with the U.S. Securities and Exchange Commission. All information in this press release is as of the date of this press release, and BeiGene undertakes no duty to update such information unless required by law.
GL-DNB-2000070. November 2020
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20201109005558/en/
Contact information
EUSA Media
Rebecca Kerr
+44 7909 703627
media@eusapharma.com
BeiGene Investors
Craig West
+1 857-302-5189
ir@beigene.com
BeiGene Media
Liza Heapes
+1 857-302-5663
media@beigene.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Ant Group’s Alipay AI Pay and AI Health App AQ Each Surpass 100 Million Users During CNY as AI Adoption Accelerates in China23.2.2026 11:48:00 EET | Press release
As AI adoption gained momentum during the 2026 Chinese New Year, Ant Group announced today that both Alipay AI Pay and its AI health app AQ have each surpassed the 100 million user milestone. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260223266559/en/ A Chinese consumer paying with Alipay AI payment solution while ordering coffee AI Payment Adoption Accelerates amid CNY AI Shopping Boom From ordering bubble tea and coffee to buying movie tickets, Chinese consumers embraced AI-powered services in everyday scenarios during this year’s holiday, driving a surge in Alipay AI Pay usage. Alipay AI Pay has surpassed 100 million users on February 23, becoming the world’s first AI-native payment product to reach this milestone. This surge highlights the broad commercial adoption of AI-powered payments. During the week of February 5-11, Alipay AI Pay processed over 120 million transactions. Launched in 2025, Alipay AI Pay is an inn
Australian Motoring Service Adds Support for Apple’s Roadside Assistance via Satellite through Infobip23.2.2026 11:43:00 EET | Press release
Global cloud communication platform Infobip supports Apple’s Roadside Assistance via satellite feature through Australian Motoring Service (AMS).* The groundbreaking technology enables drivers with iPhone 14 or later to request help and text with AMS — even in areas without cellular coverage — marking a significant advancement in automotive safety and customer service in Australia. According to the Australian Government, many parts of Australia’s regional and remote areas have no or poor mobile reception, which can make roadside assistance challenging. By leveraging Apple’s Roadside Assistance via satellite on Infobip's Cloud Contact Center solution, AMS provides critical support to stranded motorists in remote locations, including isolated highways, national parks, and mountainous regions. Rebecca Stenhouse, Chief Executive Officer at AMS, said: “At AMS, our priority is ensuring the safety and security of drivers across Australia. With Apple’s Roadside Assistance via satellite and Inf
AOP Health on Rare Diseases: Information. Collaboration. Innovation.23.2.2026 11:00:00 EET | Press release
Between 27 and 36 million1 people in Europe are living with a rare disease, yet only around six percent currently have access to an approved treatment2. Progress in diagnosis and treatment is often slowed by knowledge gaps, including the lack of clear, reliable, and patient-friendly information needed to support informed decision-making. Drawing on 30 years of experience in researching and developing therapies for rare diseases, AOP Health underscores the importance of collaboration across the healthcare community. On Rare Disease Day 2026, the company joins healthcare professionals, researchers and patient representatives in highlighting the need for closer cooperation to generate, share and better use scarce data to improve care for people living with rare diseases. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260223167500/en/ Rare Diseases: Collaboration is key. image: AdobeStock_1308212316 “Working in rare diseases sin
ŌURA Named Official Wearable of Team Finland23.2.2026 10:00:00 EET | Press release
ŌURA, maker of the world’s leading smart ring, Oura Ring, today announced a long-term partnership as the Official Wearable of Team Finland. As the exclusive provider in the category of continuous health and fitness tracking devices, ŌURA will equip Team Finland Olympic athletes with Oura Ring beginning immediately and continuing through the LA28 Olympic Games and the French Alps 2030 Winter Games. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260223559508/en/ Team Finland delivered a strong showing on the world stage at the Olympic Winter Games Milano Cortina 2026, capturing a total of six Olympic medals across a range of winter sports. During the Games, many Finnish athletes wore Oura Ring to help manage their performance and recovery. The partnership marks the start of a multi-year collaboration focused on supporting athlete preparation, recovery, and overall wellbeing across two Olympic cycles. “At ŌURA, we believe susta
AHS Tower Fully Sold During Development, Generating More Than USD 700 Million23.2.2026 09:55:00 EET | Press release
AHS Properties has confirmed that 100 percent of inventory at AHS Tower has been sold, generating more than USD 700 million in revenue during the development phase, a clear indicator of strong market demand for its flagship commercial project. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260222540070/en/ AHS Tower Fully Sold During Development on Sheikh Zayed Road (Photo: AETOSWire) Rising 69 storeys above Sheikh Zayed Road, the tower is positioned within minutes of DIFC and the Museum of the Future. Designed by internationally acclaimed architecture firm Killa Design, with interiors by AHS Atelier, it represents a defining step in AHS Properties’ expansion from ultra-luxury residential developments into Grade A commercial real estate. This demand comes amid a year of exceptional business growth in the UAE, with more than 250,000 new companies established in 2025, bringing the total number of operating companies to 1.4 mil
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom